Breaking News

Cytovance Biologics Wins Selexys Contract

Cytovance Biologics and Selexys Pharmaceutical have entered an agreement for the execution of a biopharmaceutical development and manufacturing collaboration for Anti-PSGL-1, a monoclonal antibody (mAb) being developed for treatment of inflammation associ

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cytovance Biologics and Selexys Pharmaceutical have entered an agreement for the execution of a biopharmaceutical development and manufacturing collaboration for Anti-PSGL-1, a monoclonal antibody (mAb) being developed for treatment of inflammation associated with Crohn’s disease. Cytovance will lead the cell culture process optimization, recovery and purification development, as well as provide cGMP manufacturing, technical and regulatory support for Selexys’ clinical program. “Our developme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters